Le Lézard
Classified in: Health
Subjects: WOM, MAT, MRR

FemTech Market to grow by USD 38.07 billion from 2022 to 2027, North America to account for 49% of market growth- Technavio


NEW YORK, Sept. 12, 2023 /PRNewswire/ -- The femtech market is expected to grow by USD 38.07 billion from 2022 to 2027. In addition, the momentum of the market will progress at a CAGR of 12.02% during the forecast period, according to Technavio Research. The market has been segmented by end-user (direct-to-consumer, hospitals, fertility clinics, and others), type (devices, software, services, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). North America is estimated to contribute 49% to the growth of the global market during the forecast period. The growth of the femtech market in the region will likely be driven by the presence of a well-established healthcare system that provides high-quality women's healthcare facilities through infertility clinics and hospitals. The infertility rate in smokers is twice as high as in non-smokers. In women, the risk of fertility problems increases with the number of cigarettes smoked daily. In addition, the USA was a major revenue contributor to the market in 2022 as the high rate of female infertility and related disorders, such as obesity,  is steadily increasing, thereby increasing the cases of infertility in women. Hence, these factors are expected to drive market growth in the region during the forecast period. This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment. Read PDF Sample Report

Company Profile:

Chiaro Technology Ltd., FemTec Health, Flo Health UK Ltd., HeraMED, Laboratory Corp. of America Holdings, Maven Clinic Co., Natural Cycles Nordic AB, Naya Health, Savantini Ltd., The Flex Co., Tia Inc., Uniq Health Inc., Upward Labs Holdings Inc., Willow Innovations Inc., WOOM Fertility S.L., YS BRANDS PVT. LTD., BioWink GmbH, IBREVE Ltd., NIRAMAI Health Analytix Pvt. Ltd., and Roman Health Ventures Inc.

Chiaro Technology Ltd. - The company offers Femtech products such as electric breast pumps and manual breast pumps, under its brand Elvie.

To gain access to more vendor profiles available with Technavio, buy the report!

FemTech Market: Segmentation Analysis

The market has been segmented by end-user (direct-to-consumer, hospitals, fertility clinics, and others), type (devices, software, services, and others), and geography (North America, Europe, Asia, and the Rest of the World (ROW)).

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View a PDF Sample Report

"Besides analyzing the current market scenario, our report examines historic data from 2017 to 2021"- Technavio

FemTech Market: Market Dynamics

Key Driver

The increasing prevalence of sexual dysfunctions in women is driving growth in the femtech market. Sexual dysfunction is common in women and is associated with loss of desire, difficulty reaching orgasm, and pain during sex. It is believed that the occurrence of sexual dysfunction in women is due to hormonal factors, irregular menstruation, amenorrhea, insufficient vaginal lubrication, and miscarriage. In addition, sexual dysfunction in women can be caused by various chronic diseases, such as diabetes. Diabetes is one of the most common chronic diseases in the world. Furthermore, some clinical manifestations such as overweight, hypertension, obesity, metabolic syndrome, smoking, and atherogenic dyslipidemia may occur in diabetic patients as risk factors for dysfunction.  Hence, these factors are expected to drive market growth during the forecast period. 

Identify key trends, drivers, and challenges in the market. Download to gain access to this information.

Related Reports:

The eClinical solutions market size is estimated to grow by USD 9,654.33 million at a CAGR of 13.47% between 2022 and 2027. This report covers market segmentation by end-user (pharmaceutical and biotechnology companies, contract research organizations, consulting service companies, medical device manufacturers, and others), deployment (cloud-based and on-premises), and geography (North America, Europe, Asia, and Rest of World (ROW)). Rise in clinical trials for drugs driving the growth of the market. 

The telemedicine market size is estimated to grow by USD 92.07 billion at a CAGR of 15.64% between 2022 and 2027. This report covers market segmentation by product (services and solutions), application (telehospital and teleclinic, and telephone), and geography (North America, Europe, Asia, and the Rest of the World (ROW)). The increasing healthcare cost is driving the growth of the telemedicine market. 

What are the key data covered in this femtech market report?

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by End-User

Market Segmentation by Type

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio


These press releases may also interest you

at 00:50
The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announces the results for the first two rounds of Late-Breaking Clinical Trials presented at the...

at 00:45
Revenues -5% yoy organic TDA, -3% yoy organic, a solid result given market conditions, high comparison base; volumes stabilisingBy GBU, Adecco -5%, with good results across Asia, Iberia, EEMENA, LatAm outweighed by challenging markets, particularly...

at 00:07
The pilot aims to speed up the process for safely and securely finding participants for UK clinical trials, improving efficiencies and opportunities for people to take part in research and access innovative new medicines. The pilot will test a new...

4 nov 2024
BioCity Biopharma (BioCity) announced late-breaking results of the 2-SUCCEED clinical trial of SC0062, a selective endothelin receptor type A (ETA) antagonist, for the treatment of IgA Nephropathy (IgAN). These results were presented at the Oral...

4 nov 2024
Kenvue Canada Inc., a division of Kenvue Inc. ("Kenvue"), the world's largest pure-play consumer health company by revenue and maker of iconic brands such as Tylenol®, Aveeno, Listerine® and Neutrogena®, announced the completion of its newly...

4 nov 2024
Hugel Inc., a leading global medical aesthetics company, said on Tuesday that WELLAGE, its clinical derma cosmetics brand for skin wellness, joined the festival K-beauty Boost in NYC 2024 at the Korean Cultural Center New...



News published on and distributed by: